Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
---|---|---|---|---|---|
Roivant Sciences Ltd. | Director, 10%+ Owner | $1.93B | +$337M | +21.1% | Jan 13, 2025 |
Peter Salzmann | Chief Executive Officer, Director | $23.3M | -$4.12M | -15% | Jan 15, 2025 |
Frank Torti | Director | $23M | Apr 2, 2024 | ||
Julia G. Butchko | Chief Development Officer | $14.3M | -$725K | -4.84% | Aug 21, 2024 |
William L. Macias | Chief Medical Officer | $8.69M | -$838K | -8.79% | Jan 15, 2025 |
Mark S. Levine | Chief Legal Officer | $8.12M | -$1.17M | -12.6% | Nov 20, 2024 |
Eva Renee Barnett | Chief Financial Officer | $7.86M | -$1.55M | -16.5% | Jan 15, 2025 |
George V. Migausky | Director | $4.38M | Apr 2, 2024 | ||
Andrew J. Fromkin | Director | $3.61M | Apr 2, 2024 | ||
Douglas J. Hughes | Director | $3.41M | -$155K | -4.34% | Dec 2, 2024 |
Jay S. Stout | Chief Technology Officer | $3.3M | -$420K | -11.3% | Jan 22, 2025 |
Melanie Gloria | Chief Operating Officer | $3.25M | Nov 18, 2024 | ||
Christopher Van Tuyl | Chief Legal Officer | $3.14M | Dec 16, 2024 | ||
Michael Geffner | Chief Medical Officer | $3.12M | -$347K | -10% | Jan 22, 2025 |
Atul Pande | Director | $3.04M | -$221K | -6.77% | Dec 2, 2024 |
Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
---|